vs
Side-by-side financial comparison of Dexcom (DXCM) and Revvity (RVTY). Click either name above to swap in a different company.
Dexcom is the larger business by last-quarter revenue ($1.3B vs $772.1M, roughly 1.6× Revvity). Dexcom runs the higher net margin — 21.2% vs 12.7%, a 8.5% gap on every dollar of revenue. On growth, Dexcom posted the faster year-over-year revenue change (21.6% vs 5.9%). Over the past eight quarters, Dexcom's revenue compounded faster (12.0% CAGR vs 9.0%).
Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.
Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.
DXCM vs RVTY — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $772.1M |
| Net Profit | $267.3M | $98.4M |
| Gross Margin | 62.9% | — |
| Operating Margin | 25.6% | 14.5% |
| Net Margin | 21.2% | 12.7% |
| Revenue YoY | 21.6% | 5.9% |
| Net Profit YoY | 153.6% | 3.9% |
| EPS (diluted) | $0.67 | $0.86 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $772.1M | ||
| Q3 25 | $1.2B | $698.9M | ||
| Q2 25 | $1.2B | $720.3M | ||
| Q1 25 | $1.0B | $664.8M | ||
| Q4 24 | $1.1B | $729.4M | ||
| Q3 24 | $994.2M | $684.0M | ||
| Q2 24 | $1.0B | $691.7M |
| Q1 26 | $267.3M | — | ||
| Q4 25 | $267.3M | $98.4M | ||
| Q3 25 | $283.8M | $46.7M | ||
| Q2 25 | $179.8M | $53.9M | ||
| Q1 25 | $105.4M | $42.2M | ||
| Q4 24 | $151.7M | $94.6M | ||
| Q3 24 | $134.6M | $94.4M | ||
| Q2 24 | $143.5M | $55.4M |
| Q1 26 | 62.9% | — | ||
| Q4 25 | 62.9% | — | ||
| Q3 25 | 60.5% | 53.6% | ||
| Q2 25 | 59.5% | 54.5% | ||
| Q1 25 | 56.9% | 56.5% | ||
| Q4 24 | 58.9% | — | ||
| Q3 24 | 59.7% | 56.3% | ||
| Q2 24 | 62.4% | 55.7% |
| Q1 26 | 25.6% | — | ||
| Q4 25 | 25.6% | 14.5% | ||
| Q3 25 | 20.1% | 11.7% | ||
| Q2 25 | 18.4% | 12.6% | ||
| Q1 25 | 12.9% | 10.9% | ||
| Q4 24 | 17.0% | 16.3% | ||
| Q3 24 | 15.3% | 14.3% | ||
| Q2 24 | 15.7% | 12.4% |
| Q1 26 | 21.2% | — | ||
| Q4 25 | 21.2% | 12.7% | ||
| Q3 25 | 23.5% | 6.7% | ||
| Q2 25 | 15.5% | 7.5% | ||
| Q1 25 | 10.2% | 6.4% | ||
| Q4 24 | 13.6% | 13.0% | ||
| Q3 24 | 13.5% | 13.8% | ||
| Q2 24 | 14.3% | 8.0% |
| Q1 26 | $0.67 | — | ||
| Q4 25 | $0.67 | $0.86 | ||
| Q3 25 | $0.70 | $0.40 | ||
| Q2 25 | $0.45 | $0.46 | ||
| Q1 25 | $0.27 | $0.35 | ||
| Q4 24 | $0.37 | $0.77 | ||
| Q3 24 | $0.34 | $0.77 | ||
| Q2 24 | $0.35 | $0.45 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $917.7M | $919.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.7B | $7.3B |
| Total Assets | $6.3B | $12.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $917.7M | — | ||
| Q4 25 | $917.7M | $919.9M | ||
| Q3 25 | $1.8B | $931.4M | ||
| Q2 25 | $1.2B | $991.8M | ||
| Q1 25 | $904.9M | $1.1B | ||
| Q4 24 | $606.1M | $1.2B | ||
| Q3 24 | $621.2M | $1.2B | ||
| Q2 24 | $939.2M | $2.0B |
| Q1 26 | $2.7B | — | ||
| Q4 25 | $2.7B | $7.3B | ||
| Q3 25 | $2.7B | $7.4B | ||
| Q2 25 | $2.6B | $7.6B | ||
| Q1 25 | $2.3B | $7.6B | ||
| Q4 24 | $2.1B | $7.7B | ||
| Q3 24 | $2.0B | $7.9B | ||
| Q2 24 | $2.4B | $7.9B |
| Q1 26 | $6.3B | — | ||
| Q4 25 | $6.3B | $12.2B | ||
| Q3 25 | $7.5B | $12.1B | ||
| Q2 25 | $7.3B | $12.4B | ||
| Q1 25 | $6.8B | $12.4B | ||
| Q4 24 | $6.5B | $12.4B | ||
| Q3 24 | $6.4B | $12.8B | ||
| Q2 24 | $6.8B | $13.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $182.0M |
| Free Cash FlowOCF − Capex | — | $161.8M |
| FCF MarginFCF / Revenue | — | 21.0% |
| Capex IntensityCapex / Revenue | — | 2.6% |
| Cash ConversionOCF / Net Profit | — | 1.85× |
| TTM Free Cash FlowTrailing 4 quarters | — | $509.4M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $294.0M | $182.0M | ||
| Q3 25 | $659.9M | $138.5M | ||
| Q2 25 | $303.0M | $134.3M | ||
| Q1 25 | $183.8M | $128.2M | ||
| Q4 24 | $301.4M | $174.2M | ||
| Q3 24 | $199.5M | $147.9M | ||
| Q2 24 | $279.4M | $158.6M |
| Q1 26 | — | — | ||
| Q4 25 | $192.1M | $161.8M | ||
| Q3 25 | $579.4M | $120.0M | ||
| Q2 25 | $208.9M | $115.5M | ||
| Q1 25 | $96.8M | $112.2M | ||
| Q4 24 | $176.8M | $149.8M | ||
| Q3 24 | $88.3M | $125.6M | ||
| Q2 24 | $213.3M | $136.6M |
| Q1 26 | — | — | ||
| Q4 25 | 15.3% | 21.0% | ||
| Q3 25 | 47.9% | 17.2% | ||
| Q2 25 | 18.1% | 16.0% | ||
| Q1 25 | 9.3% | 16.9% | ||
| Q4 24 | 15.9% | 20.5% | ||
| Q3 24 | 8.9% | 18.4% | ||
| Q2 24 | 21.2% | 19.7% |
| Q1 26 | — | — | ||
| Q4 25 | 8.1% | 2.6% | ||
| Q3 25 | 6.7% | 2.6% | ||
| Q2 25 | 8.1% | 2.6% | ||
| Q1 25 | 8.4% | 2.4% | ||
| Q4 24 | 11.2% | 3.4% | ||
| Q3 24 | 11.2% | 3.3% | ||
| Q2 24 | 6.6% | 3.2% |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 1.85× | ||
| Q3 25 | 2.33× | 2.97× | ||
| Q2 25 | 1.69× | 2.49× | ||
| Q1 25 | 1.74× | 3.03× | ||
| Q4 24 | 1.99× | 1.84× | ||
| Q3 24 | 1.48× | 1.57× | ||
| Q2 24 | 1.95× | 2.87× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DXCM
Segment breakdown not available.
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
